Top-News
Quelle: - © gilaxia / E+ / Getty Images:
INOVIO to Present at Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa., April 30, 2025
PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. INOVIO will also present for the first time data on the long-term clinical effect of lead candidate INO-3107 at the American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM), the largest meeting of otolaryngologists in the U.S.
Citizens JMP Life Sciences Conference (NY)
Date: May 8
Time: 11:30am EDT
Format: Fireside Chat
(audio webcast available here: https://wsw.com/webcast/jmp65/ino/1544620)
European Laryngological Society Annual Congress (Warsaw, PL)
Date: May 9
Oral presentation: DNA immunotherapy, INO-3107, generates targeted immunologic response and results in surgery reduction for 81% of adults with recurrent respiratory papillomatosis in year 1
American Society of Gene and Cell Therapy (New Orleans, LA)
Date: May 13
Poster Abstract Session: Successful Treatment of Recurrent Respiratory Papillomatosis with INO-3107 is Irrespective of Papilloma Microenvironment and Molecular Subtype
ABEA at COSM (New Orleans, LA)
Date: May 15
Oral Presentation: DNA Immunotherapy (INO-3107) Durability and Long-Term Clinical Effect in Treatment of Recurrent Respiratory Papillomatosis Caused by HPV 6 & 11
Available abstracts will be shared on INOVIO's website following presentations. An audio replay of the Citizens JMP webcast will be available for 90 days after the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-and-investor-conferences-302442322.html
SOURCE INOVIO Pharmaceuticals, Inc.
Für dich aus unserer Redaktion zusammengestellt
Dein Kommentar zum Artikel im Forum
Jetzt anmelden und diskutieren
Registrieren
Login
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
